Informing selection of drugs for COVID-19 treatment through adverse events analysis

Abstract Coronavirus disease 2019 (COVID-19) is an ongoing pandemic and there is an urgent need for safe and effective drugs for COVID-19 treatment. Since developing a new drug is time consuming, many approved or investigational drugs have been repurposed for COVID-19 treatment in clinical trials. T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wenjing Guo, Bohu Pan, Sugunadevi Sakkiah, Zuowei Ji, Gokhan Yavas, Yanhui Lu, Takashi E. Komatsu, Madhu Lal-Nag, Weida Tong, Tucker A. Patterson, Huixiao Hong
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/cec1715e9fd24f53a1ff4e77983d08f9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!